Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07031323 · ClinicalTrials.gov registry record · NA

OnTrackCF: Engagement, Feasibility, and Acceptability Study

A NA study of Cystic Fibrosis (CF) and Cystic Fibrosis - Complete, sponsored by Boston Children's Hospital.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
3
Study locations

NCT07031323 is a NA study of Cystic Fibrosis (CF) and Cystic Fibrosis - Complete that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 60 participants, below the 137-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (56% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07031323, a NA study of Cystic Fibrosis (CF) and Cystic Fibrosis - Complete, is actively recruiting participants, sponsored by Boston Children's Hospital.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
3
Study locations

Study Summary

This is a multi-site, nonrandomized study using mixed methods approach to evaluate the feasibility, acceptability, and user engagement of OnTrackCF for adults with Cystic Fibrosis (AWCF).

Interventions

  • BEHAVIORAL OnTrackCF

Study Locations (3)

Alabama

  • University of Alabama-Birmingham - Birmingham

Maryland

  • Johns Hopkins University - Baltimore

Massachusetts

  • Boston Children's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-11-20
Est. Completion 2026-12
Phase NA

Sponsor

Boston Children's Hospital

462 total trials

What the Registry Record Tells You About NCT07031323

The ClinicalTrials.gov registry entry for NCT07031323 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 137-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (56% lower). The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cystic Fibrosis (CF) appearing as the primary indexed condition, and to 1 intervention - of which OnTrackCF is the first listed.

NCT07031323 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Alabama, Maryland, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07031323 about?

NCT07031323 is a clinical study titled "OnTrackCF: Engagement, Feasibility, and Acceptability Study". This is a multi-site, nonrandomized study using mixed methods approach to evaluate the feasibility, acceptability, and user engagement of OnTrackCF for adults with Cystic Fibrosis (AWCF).

What is the current status of trial NCT07031323?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-11-20. Estimated completion is 2026-12.

What conditions does trial NCT07031323 study?

This clinical trial studies the following conditions: Cystic Fibrosis (CF), Cystic Fibrosis - Complete.

What interventions are being tested in trial NCT07031323?

The interventions under investigation include: OnTrackCF (BEHAVIORAL).

Who is sponsoring clinical trial NCT07031323?

This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07031323 being conducted?

This trial has 3 study locations across Alabama, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis (CF)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.